Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment

Abstract

Background Normative data are necessary for validation of new outcome measures. Recently, the 95th centile of stride speed was qualified by the European Medicines Agency as a valid secondary outcome for clinical trials in subjects with Duchenne muscular dystrophy. This study aims to obtain normative data on spontaneous stride velocity and length in a non-controlled environment and their evolution after 12 months. Method Ninety-one healthy volunteers (50 females, 41 males), with a mean age of 16 years and 2 months, were recruited and assessed at baseline and 12 months later. The 4-stair climb, 6-min walk test, 10-m walk test and rise from floor assessments were performed. Stride length, stride velocity, and the distance walked per hour were studied in an everyday setting for one month after each evaluation. Results Of the 91 subjects assessed, 82 provided more than 50 h of recordings at baseline; and 73 subjects provided the same at the end of the year. We observed significant positive correlations of the stride length with age and height of participants, and a significant increase of the median stride length in children after the period. In this group, the 95th centile stride velocity was not correlated with age and was stable after one year. All measures but the 10MWT were stable in adults after a one-year period. Conclusion This study provides with data on the influence of age, height, and gender on stride velocity and length as well as accounting for natural changes after one year in controls.

Mobile and wearable technologies for the analysis of Ten Meter Walk Test: A concise systematic review

“…The authors of [ 42 ] used the ActiMyo® device (Sysnav, Vernon, France) composed of accelerometer and magnetometer sensors to gather normative information on the length and speed of spontaneous strides in an uncontrolled setting, as well as how they changed over a year. The study included 82 participants (46 females and 36 males) aged between 6 and 85 years old to evaluate the stride length and stride velocity during the Ten Meter Walk Test performance.…”

“…It also quantifies the therapeutic impact on functional ambulation. Time; Motion Chronometer; Accelerometer Physical problems Stroke Poleur et al [ 42 ] 2021 46 females and 36 males The authors want to gather normative information on spontaneous stride length and velocity in an uncontrolled context and its changes over 12 months. Motion; Magnetic ActiMyo® device; Accelerometer; Magnetometer N/A N/A Tan et al [ 43 ] 2021 2 females and 9 males The authors examined how much daily acute intermittent hypoxia and walking exercise improved intralimb motor coordination and overground walking performance.…”

Home‐based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy

“…In contrast, magneto‐inertial technology allows for a continuous and objective assessment of a patient's daily motor activity and is much less influenced by day‐to‐day fluctuations. Magneto‐inertial technology has been widely used in different fields of medicine including in evaluation of subjects with neuromuscular disorders 10–12 and in controls 13 . However, with the exceptions of DMD 3 and SMA 13 populations, only cumulative variables have been studied thus far.…”

“…Magneto‐inertial technology has been widely used in different fields of medicine including in evaluation of subjects with neuromuscular disorders 10–12 and in controls 13 . However, with the exceptions of DMD 3 and SMA 13 populations, only cumulative variables have been studied thus far. A major limitation of actimetry using cumulative variables is the high variability induced by weather or social factors.…”

Presentation1.pdf

“…On the other side, functional outcome measures are very much dependent on both the observer's opinion and the patient's fatigue and motivation. The use of endpoints based on continuous monitoring with wearable technologies, such as the 95th percentile stride velocity, has the potential to dramatically decrease the number of patients needed as well as the study duration (Haberkamp et al, 2019;Poleur et al, 2021). Now, breakthroughs in the fields of genetic therapies bring several opportunities in the preclinical and clinical pipeline of DMD, which need to be efficiently assessed in clinical trials.…”